Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 199

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Late-onset anti–NMDA receptor encephalitis

Open access
Titulaer, Maarten J., McCracken, Lindsey, Gabilondo, Iñigo, Iizuka, Takahiro, Kawachi, Izumi, Bataller, L., Torrents, A., Rosenfeld, Myrna R., Balice-Gordon, Rita, Graus, Francesc, Dalmau, Josep · 2013 · Neurology

Abstract

OBJECTIVE: To describe the clinical features and outcome of anti-NMDA receptor (NMDAR) encephalitis in patients ≥45 years old. METHOD: Observational cohort study. RESULTS: In a cohort of 661 patients with anti-NMDAR encephalitis, we identified 31 patients ≥45 years old. Compared with younger adults (18-44 years), older patients were more often male (45% vs. 12%, p < 0.0001), had lower frequency of tumors (23% vs. 51%, p = 0.002; rarely teratomas), had longer median time to diagnosis (8 vs 4 weeks, p = 0.009) and treatment (7 vs. 4 weeks, p = 0.039), and had less favorable outcome (modified Rankin Scale score 0-2 at 2 years, 60% vs. 80%, p < 0.026). In multivariable analysis, younger age (odds ratio [OR] 0.15, confidence interval [CI] 0.05-0.39, p = 0.0001), early treatment (OR 0.60, CI 0.47-0.78, p < 0.0001), no need for intensive care (OR 0.09, CI 0.04-0.22, p < 0.0001), and longer follow-up (p < 0.0001) were associated with good outcome. Rituximab and cyclophosphamide were effective when first-line immunotherapies failed (OR 2.93, CI 1.10-7.76, p = 0.031). Overall, 60% of patients older than 45 years had full or substantial recovery at 24 months follow-up. CONCLUSIONS: Anti-NMDAR encephalitis is less severe in patients ≥45 years old than in young adults, but the outcome is poorer in older patients. In this age group, delays in diagnosis and treatment are more frequent than in younger patients. The frequency of underlying tumors is low, but if present they are usually carcinomas instead of teratomas in younger patients. Early and aggressive immunotherapy will likely improve the clinical outcome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0b013e3182a4a49c

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 199

Metadata

Authors
Titulaer, M. J., McCracken, L., Gabilondo, I., Iizuka, T., Kawachi, I., Bataller, L., Torrents, A., Rosenfeld, M. R., Balice-Gordon, R., Graus, F., & Dalmau, J.
Venue
Neurology
Published
2013-09-17
Volume
81
Issue
12
Pages
1058-1063
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2096422832
Cited by
199
References
5
FWCI
7.22
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Late-onset anti–NMDA receptor encephalitis. https://app.cochat.ai/papers/10.1212/wnl.0b013e3182a4a49c
The paper
Titulaer, M. J., McCracken, L., Gabilondo, I., Iizuka, T., Kawachi, I., Bataller, L., Torrents, A., Rosenfeld, M. R., Balice-Gordon, R., Graus, F., & Dalmau, J. (2013). Late-onset anti–NMDA receptor encephalitis. Neurology. https://doi.org/10.1212/wnl.0b013e3182a4a49c

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.